Navigation Links
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Date:12/21/2007

te Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Centocor does not undertake to update any forward-looking statements as a result of new information or future events or developments.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the do
'/>"/>

SOURCE Schering-Plough Corporation; Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
10. NUCRYST and Smith & Nephew Revise Agreements
11. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... Zensah®, the leader in compression technology and sports medicine, has ... . The wrist support features an adjustable velcro strap and ... Epicondylitis, more commonly referred to as tennis elbow and golfers ... the tendons attached to the outside of the elbow. Although ... work the wrist and fingers turn into a tendon that ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Manufacturers of ... with organic ways to achieve a younger appearance. The ... buyer's guide to help men and women explore the ... The details that are presented in the posted guide ... price information for consumers. On drawback to some natural ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... (GFRP) Composites Market By Raw Material, By Manufacturing ... & Others) & By Geography – Global Trends ... global GFRP Composites market with an analysis and ... market data tables and 107 figures spread through ...
(Date:7/27/2014)... from The University of Manchester have discovered why medication to ... published in Nature Medicine , show that drugs widely ... , In the UK pneumonia, which is caused ... year and is more serious for babies, young children, the ... , More than 5 million people in the UK are ...
Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2
... good judges of affordability, but a new study reveals that ... you think about a larger pool of resources (such as ... your wallet). Through a series of four experiments, researchers ... time. Counting calories" Youre more likely to eat that slice ...
... from the University of California San Francisco has identified ... woman is likely to develop subsequent invasive cancer after ... cancer. The research, published by Cell Press in the ... can be used to determine whether a woman should ...
... GREEN BAY, Wis., Nov. 12 Shopko announced ... position of President and Chief,Merchandising Officer. Jones will ... marketing activities of the regional mass retailer. ... roles in the,department store sector, mid-tier chain stores ...
... Va., Nov. 12 Conservationists and scientists,from around ... and Research Symposium, in Orlando, Florida. The Symposium ... Bailey Center for Elephant,Conservation(R) and the International Elephant ... two day global Conference on Elephant,Tuberculosis Research. The ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
... Hazelden Foundation offers Barry McMillen - Nicotine Cessation Expert and ... ... Nov. 12 Using tobacco isn,t just a,habit; it,s an addiction. ... for over 50 years. The same principles,of the Hazelden treatment experience ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
... The Wound Care Manager ... for patient assessment and data ... care. This application was developed ... Wound Care along with the ...
... specifically for the Palm Organizers to ... rounds. It is intended to record ... that are requested by the senior ... round examinations and to record the ...
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Medicine Products: